Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.49 USD | -5.42% | +5.17% | -17.81% |
03:40pm | CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate | MT |
05-23 | CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.81% | 827M | |
+51.84% | 63.85B | |
-2.26% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.28% | 26.52B | |
-21.49% | 18.69B | |
+2.76% | 12.73B | |
+22.02% | 12.11B | |
+27.58% | 12.07B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- Nykode Therapeutics Names CureVac Exec As New Chief Development Officer